Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 mild to moderate meta-analysis

Fontanesi
 
NCT04348409
RCTnitazoxanideplaceboCOVID-19 mild to moderateNA
25/25 no results
    Silva
     
    NCT04463264
    RCTnitazoxanideplaceboCOVID-19 mild to moderatehigh
    33/13 inconclusive
      Rocco
       
      NCT04552483
      RCTnitazoxanideplaceboCOVID-19 mild to moderatehigh
      238/237 inconclusive
      • inconclusive 19 % decrease in clinical improvement,clinical improvement (7-day) (PE) but with a low degree of certainty due to high risk of bias

      PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
      Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).